Virpax Pharmaceuticals, Inc. VRPX has engaged two physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for NobrXiol. Their involvement with this program is expected to include advising on trial design, regulatory pathway development and patient recruitment. Additionally, it is anticipated that they will support Virpax with patient advocacy groups and grant applications.
NobrXiol is the company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults that utilizes the Nanomerics Molecular Envelope Technology as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve.
Sommerville is a board-certified neurologist with over 30 years of experience working with major multinational pharmaceutical companies enabling approvals for numerous drugs with both the FDA and the EMEA. He is a recognized authority in drug development with an expertise in anti-epileptic drugs, pain, and abuse-deterrent opioids. Dr. Sommerville was in charge of phases II and III of the U.S. epilepsy trials for cannabidiol. The lead cannabinoid, CBD (Epidiolex), received FDA approval in June of 2018.
Fried is an experienced clinical leader in epilepsy and neurology and a practicing epileptologist. He currently serves as an attending physician in the Pediatric Regional Epilepsy Program at the Children’s Hospital of Philadelphia, as well as an assistant professor of clinical neurology at the University of Pennsylvania and is a corporate advisory committee member of the American Epilepsy Society.
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.
Photo by Tim Foster on Unsplash
Related News
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.